Compare ITRM & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRM | ELUT |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 23.3M |
| IPO Year | 2018 | 2020 |
| Metric | ITRM | ELUT |
|---|---|---|
| Price | $0.34 | $0.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.00 | $7.00 |
| AVG Volume (30 Days) | ★ 968.4K | 452.6K |
| Earning Date | 03-20-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $390,000.00 | ★ $21,746,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $193.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $0.26 | $0.50 |
| 52 Week High | $1.75 | $3.46 |
| Indicator | ITRM | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 45.51 | 63.97 |
| Support Level | $0.31 | $0.74 |
| Resistance Level | $0.39 | $1.08 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 33.84 | 67.47 |
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.